Citius Q2 FY2023 net loss $10.5M ($0.07/share); Halo-Lido Phase 2b topline expected Q2 2023

Citius Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.10

Net loss of $10.5M ($0.07 per share) for fiscal Q2 ended March 31, 2023, vs $7.6M ($0.05) a year ago.
Cash $29.1M as of March 31, 2023; raised $15M in May 2023 registered direct offering, extending runway through May 2024.
Halo-Lido Phase 2b hemorrhoid trial completed; topline results expected by end of calendar Q2 2023.
Mino-Lok Phase 3 trial at 85 of 92 required events; enrollment ongoing aiming for completion in 2023.
I/ONTAK BLA under FDA review with PDUFA date July 28, 2023; spinoff preparation continues.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Citius Pharmaceuticals, Inc. reported the fiscal second quarter ended March 31, 2023 results: net income Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March, EPS ($0.07) and ($0.10) per share.

Period: the fiscal second quarter ended March 31, 2023
Net income: Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March
EPS: ($0.07) and ($0.10) per share
Result: reported results

Exact text from the filing

r ($0.07) and ($0.10) per share for the three and six months ended March 31, 2023, respectively, compared to a net loss of $7.6 million

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-039083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.